Cost-Utility Analysis of Fentanyl Sublingual Formulation in the Treatment of Breakthrough Pain in Adults With Cancer, Already on Opioid Maintenance Therapy for Chronic Cancer Pain in Italy
Author(s)
Paoletti M1, Marcellusi A2, Mennini FS3
1Economic Evaluation and HTA (EEHTA CEIS), Department of Economics and Finance, Faculty of Economics, University of Rome “Tor Vergata”, ROMA, RM, Italy, 2Economic Evaluation and HTA (EEHTA CEIS), Department of Economics and Finance, Faculty of Economics, University of Rome “Tor Vergata”, Rome, Italy, 3Economic Evaluation and HTA (EEHTA CEIS), Department of Economics and Finance, Faculty of Economics, University of Rome “Tor Vergata”, Roma (RM), RM, Italy
Presentation Documents
CONCLUSIONS:
Considering a willingness to pay threshold as reported by the AIES Guidelines (€ 25,000 - € 40,000), fentanyl sublingual formulation is cost-effective compared to oral morphine.Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
EE176
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
SDC: Oncology, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)